Therapeutic Strategies for Restoring Tau Homeostasis
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Normal tau homeostasis is achieved when the synthesis, processing, and degradation of the protein is balanced. Together, the pathways that regulate tau homeostasis ensure that the protein is at the proper levels and that its posttranslational modifications and subcellular localization are appropriately controlled. These pathways include the enzymes responsible for posttranslational modifications, those systems that regulate mRNA splicing, and the molecular chaperones that control tau turnover and its binding to microtubules. In tauopathies, this delicate balance is disturbed. Tau becomes abnormally modified by posttranslational modification, it loses affinity for microtubules, and it accumulates in proteotoxic aggregates. How and why does this imbalance occur? In this review, we discuss how molecular chaperones and other components of the protein homeostasis (e.g., proteostasis) network normally govern tau quality control. We also discuss how aging might reduce the capacity of these systems and how tau mutations might further affect this balance. Finally, we discuss how small-molecule inhibitors are being used to probe and perturb the tau quality-control systems, playing a particularly prominent role in revealing the logic of tau homeostasis. As such, there is now interest in developing these chemical probes into therapeutics, with the goal of restoring normal tau homeostasis to treat disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“Genome-wide association studies have implicated the molecular chaperone clusterin in AD (Harold et al. 2009; Lambert et al. 2009).”
Propagation of Tau Pathology in a Model of Early Alzheimer's Disease
de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.033 · Cited by 1,427
Propagation of Tau Misfolding from the Outside to the Inside of a Cell
Frost, B., Jacks, R. L., & Diamond, M. I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808759200 · Cited by 1,252 · cited 1×
“The mechanisms of cell-to-cell transmission remain unclear, but cell and animal models are in development (Frost et al. 2009; Kfoury et al. 2012; Yanamandra et al. 2013; Holmes et al. 2014), which will provide, for the first time, an opportunity to target proteins important in this process.”
BackgroundTau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Augustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998 · cited 1×
“Indeed, antibodies recognizing phospho-epitopes, such as AT8, AT180, and PHF1, are commonly used to mark neuropathology in all tauopathies (Mercken et al. 1992; Augustinack et al. 2002).”
BackgroundGoedert, M., & Jakes, R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07870.x · Cited by 929 · cited 4×
“2000) and nucleate microtubule assembly better than the 3R isoforms (Goedert and Jakes 1990).”
BackgroundInfluentialAssociation of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy
Baker, M., Litvan, I., Houlden, H., Adamson, J., Dickson, D., Perez-Tur, J., Hardy, J., Lynch, T., Bigio, E., & Hutton, M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.4.711 · Cited by 781 · cited 2×
“There are also reports of risk factors linked to MAPT, including the A152T variant within the protein coding region (Coppola et al. 2012) and the MAPT variation associated with the H1 haplotype (Baker et al. 1999).”
BackgroundCHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation
Petrucelli, L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh083 · Cited by 723
The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein
Lu, P.-J., Wulf, G., Zhou, X. Z., Davies, P., & Lu, K. P. (1999) · Nature · doi:10.1038/21650 · Cited by 721
Proteopathic tau seeding predicts tauopathy in vivo
Holmes, B. B., Furman, J. L., Mahan, T. E., Yamasaki, T. R., Mirbaha, H., Eades, W. C., Belaygorod, L., Cairns, N. J., Holtzman, D. M., & Diamond, M. I. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411649111 · Cited by 696 · cited 1×
“The mechanisms of cell-to-cell transmission remain unclear, but cell and animal models are in development (Frost et al. 2009; Kfoury et al. 2012; Yanamandra et al. 2013; Holmes et al. 2014), which will provide, for the first time, an opportunity to target proteins important in this process.”
BackgroundStructural Polymorphism of 441-Residue Tau at Single Residue Resolution
Mukrasch, M. D., Bibow, S., Korukottu, J., Jeganathan, S., Biernat, J., Griesinger, C., Mandelkow, E., & Zweckstetter, M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000034 · Cited by 652 · cited 1×
“Nuclear magnetic resonance (NMR) studies have shown that tau proteins are disordered in solution, only transiently sampling secondary structures (Mukrasch et al. 2009).”
BackgroundDickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29715 · Cited by 642 · cited 9×
“Treatment with PU24FCl reduces hyperphosphorylated tau and insoluble tau in cellular models (Dickey et al. 2007; Luo et al. 2007), whereas no effect is seen on normal tau (Luo et al. 2007), suggesting that Hsp90 and its cochaperones preferentially act on abnormal tau.”
BackgroundInfluentialTau fragmentation, aggregation and clearance: the dual role of lysosomal processing
Wang, Y., Martinez-Vicente, M., Krüger, U., Kaushik, S., Wong, E., Mandelkow, E.-M., Cuervo, A. M., & Mandelkow, E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp367 · Cited by 617 · cited 3×
“Chaperone-mediated autophagy and the UPS are the major clearance pathways for removing tau (Wong et al. 2008; Wang et al. 2009; Ozcelik et al. 2013).”
BackgroundYanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574 · cited 1×
“The mechanisms of cell-to-cell transmission remain unclear, but cell and animal models are in development (Frost et al. 2009; Kfoury et al. 2012; Yanamandra et al. 2013; Holmes et al. 2014), which will provide, for the first time, an opportunity to target proteins important in this process.”
BackgroundTrans-cellular Propagation of Tau Aggregation by Fibrillar Species
Kfoury, N., Holmes, B. B., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.346072 · Cited by 552 · cited 1×
“The mechanisms of cell-to-cell transmission remain unclear, but cell and animal models are in development (Frost et al. 2009; Kfoury et al. 2012; Yanamandra et al. 2013; Holmes et al. 2014), which will provide, for the first time, an opportunity to target proteins important in this process.”
BackgroundKampers, T., Friedhoff, P., Biernat, J., Mandelkow, E.-M., & Mandelkow, E. (1996) · FEBS Letters · doi:10.1016/s0014-5793(96)01386-5 · Cited by 548
Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits
Min, S.-W., Chen, X., Tracy, T. E., Li, Y., Zhou, Y., Wang, C., Shirakawa, K., Minami, S. S., Defensor, E., Mok, S. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3951 · Cited by 516 · cited 2×
“At least three acetylation sites on tau, at residues K174, K280, and K281, correlate with other markers of tau neuropathology (Irwin et al. 2012; Min et al. 2015).”
BackgroundSelf-citationAlzheimer brain-derived tau oligomers propagate pathology from endogenous tau
Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Guerrero-Munoz, M. J., Kiritoshi, T., Neugebauer, V., Jackson, G. R., & Kayed, R. (2012) · Scientific Reports · doi:10.1038/srep00700 · Cited by 502
Tau promotes neurodegeneration through global chromatin relaxation
Frost, B., Hemberg, M., Lewis, J., & Feany, M. B. (2014) · Nature Neuroscience · doi:10.1038/nn.3639 · Cited by 495 · cited 2×
“Recent reviews further detail the links between tau and neurodegeneration (Spillantini and Goedert 2013; Frost et al. 2014) and outline the features of the animal models (see Noble et al.”
BackgroundThe prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-β production
Pastorino, L., Sun, A., Lu, P.-J., Zhou, X. Z., Balastik, M., Finn, G., Wulf, G., Lim, J., Li, S.-H., Li, X., et al. (2006) · Nature · doi:10.1038/nature04543 · Cited by 487 · cited 1×
“One major protein in this class, Pin1, is highly expressed in neurons and is implicated in Ab pathology (Pastorino et al. 2006) and tauopathies like FTDP-17 and AD (Yotsumoto et al. 2009; Kimura et al. 2013).”
BackgroundFrontotemporal Dementia and Corticobasal Degeneration in a Family with a P301S Mutation in Tau
Bugiani, O., Murrell, J. R., Giaccone, G., Hasegawa, M., Ghigo, G., Tabaton, M., Morbin, M., Primavera, A., Carella, F., Solaro, C., et al. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199906000-00011 · Cited by 450
LoPresti, P., Szuchet, S., Papasozomenos, S. C., Zinkowski, R. P., & Binder, L. I. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.22.10369 · Cited by 388
Histone deacetylase 6 interacts with the microtubule‐associated protein tau
Ding, H., Dolan, P. J., & Johnson, G. V. W. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05564.x · Cited by 387
Arendt, T., Stieler, J., Strijkstra, A. M., Hut, R. A., Rüdiger, J., Van der Zee, E. A., Harkany, T., Holzer, M., & Härtig, W. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-18-06972.2003 · Cited by 357 · cited 1×
“However, a clear causeand-effect relationship between hyperphosphorylation and disease onset remains to be demonstrated, and tau hyperphosphorylation is associated with normal development (Kenessey and Yen 1993) and animal hibernation (Arendt et al. 2003).”
BackgroundToward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments
Barghorn, S., & Mandelkow, E. (2002) · Biochemistry · doi:10.1021/bi026469j · Cited by 341
Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments
Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Titani, K., & Ihara, Y. (1993) · Neuron · doi:10.1016/0896-6273(93)90063-w · Cited by 332 · cited 1×
“Multiple ubiquitination sites have been identified by mass spectroscopy analysis of PHF–tau preparations (Morishima-Kawashima et al. 1993; Cripps et al. 2006; Thomas et al. 2012); however, the requirement of these specific sites for the degradation of tau has not been confirmed.”
BackgroundSites of Tau Important for Aggregation Populate β-Structure and Bind to Microtubules and Polyanions
Mukrasch, M. D., Biernat, J., von Bergen, M., Griesinger, C., Mandelkow, E., & Zweckstetter, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501565200 · Cited by 324
Hsp90-Tau complex reveals molecular basis for specificity in chaperone action
Karagöz, G. E., Duarte, A. M. S., Akoury, E., Ippel, H., Biernat, J., Morán Luengo, T., Radli, M., Didenko, T., Nordhues, B. A., Veprintsev, D. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.037 · Cited by 318 · cited 9×
“Two aggregation motifs within the MTBRs are required for this process, and several mutations in this region prevent self-assembly (von Bergen et al. 2000, 2001).”
BackgroundInfluentialAntisense Reduction of Tau in Adult Mice Protects against Seizures
DeVos, S. L., Goncharoff, D. K., Chen, G., Kebodeaux, C. S., Yamada, K., Stewart, F. R., Schuler, D. R., Maloney, S. E., Wozniak, D. F., Rigo, F., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2107-13.2013 · Cited by 311 · cited 1×
“One way of clearing tau is to target it at the mRNA level with antisense oligonucleotides (DeVos et al. 2013).”
BackgroundAcetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies
Irwin, D. J., Cohen, T. J., Grossman, M., Arnold, S. E., Xie, S. X., Lee, V. M.-Y., & Trojanowski, J. Q. (2012) · Brain · doi:10.1093/brain/aws013 · Cited by 281 · cited 1×
“At least three acetylation sites on tau, at residues K174, K280, and K281, correlate with other markers of tau neuropathology (Irwin et al. 2012; Min et al. 2015).”
BackgroundCastillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278 · cited 1×
“…it is likely that oligomers are especially detrimental to cells, because they decrease cell viability more potently than tau fibrils (Flach et al. 2012), and antibodies against oligomers of tau are protective when administered to animal models of tauopathy (Castillo-Carranza et al. 2014, 2015).”
BackgroundSingle-molecule investigation of the interference between kinesin, tau and MAP2c
Seitz, A., Kojima, H., Oiwa, K., Mandelkow, E.-M., Song, Y.-H., & Mandelkow, E. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf503 · Cited by 257 · cited 2×
“In addition to tubulin, tau also binds actin (Moraga et al. 1993), kinesin (Jancsik et al. 1996; Seitz et al. 2002), and dynactin (Magnani et al. 2007; Patterson et al. 2011).”
BackgroundCoppola, G., Chinnathambi, S., Lee, J. J., Dombroski, B. A., Baker, M. C., Soto-Ortolaza, A. I., Lee, S. E., Klein, E., Huang, A. Y., Sears, R., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds161 · Cited by 240 · cited 2×
“There are also reports of risk factors linked to MAPT, including the A152T variant within the protein coding region (Coppola et al. 2012) and the MAPT variation associated with the H1 haplotype (Baker et al.”
BackgroundAkt and CHIP coregulate tau degradation through coordinated interactions
Dickey, C. A., Koren, J., Zhang, Y.-J., Xu, Y.-F., Jinwal, U. K., Birnbaum, M. J., Monks, B., Sun, M., Cheng, J. Q., Patterson, C., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709180105 · Cited by 226
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.
Ozcelik, S., Fraser, G., Castets, P., Schaeffer, V., Skachokova, Z., Breu, K., Clavaguera, F., Sinnreich, M., Kappos, L., Goedert, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062459 · Cited by 226
Early N-Terminal Changes and Caspase-6 Cleavage of Tau in Alzheimer's Disease
Horowitz, P. M., Patterson, K. R., Guillozet-Bongaarts, A. L., Reynolds, M. R., Carroll, C. A., Weintraub, S. T., Bennett, D. A., Cryns, V. L., Berry, R. W., & Binder, L. I. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1988-04.2004 · Cited by 215
The Co-chaperone p23 Arrests the Hsp90 ATPase Cycle to Trap Client Proteins
McLaughlin, S. H., Sobott, F., Yao, Z.-P., Zhang, W., Nielsen, P. R., Grossmann, J. G., Laue, E. D., Robinson, C. V., & Jackson, S. E. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.11.085 · Cited by 196 · cited 1×
“The co-chaperone p23, which binds to the N-terminal ATP-binding domain, also stabilizes the closed state of Hsp90 and traps substrate clients while accelerating ATP hydrolysis (McLaughlin et al. 2006).”
BackgroundTau Oligomers Impair Artificial Membrane Integrity and Cellular Viability
Flach, K., Hilbrich, I., Schiffmann, A., Gärtner, U., Krüger, M., Leonhardt, M., Waschipky, H., Wick, L., Arendt, T., & Holzer, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.396176 · Cited by 188 · cited 2×
“Although it is not yet clear which tau structures are most toxic, it is likely that oligomers are especially detrimental to cells, because they decrease cell viability more potently than tau fibrils (Flach et al. 2012), and antibodies against oligomers of tau are protective when administered to animal models of tauopa…”
BackgroundCaspase-cleaved Tau Expression Induces Mitochondrial Dysfunction in Immortalized Cortical Neurons
Quintanilla, R. A., Matthews-Roberson, T. A., Dolan, P. J., & Johnson, G. V. W. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808908200 · Cited by 170 · cited 2×
“2006), preferential degradation by autophagy (Dolan and Johnson 2010), mitochondrial dysfunction (Quintanilla et al. 2009), and enhanced secretion from cells (Plouffe et al.”
BackgroundHöglinger, G. U., Huppertz, H., Wagenpfeil, S., Andrés, M. V., Belloch, V., León, T., del Ser, T., & for the TAUROS MRI Investigators (2014) · Movement Disorders · doi:10.1002/mds.25815 · Cited by 161
Castillo-Carranza, D. L., Guerrero-Muñoz, M. J., Sengupta, U., Hernandez, C., Barrett, A. D. T., Dineley, K., & Kayed, R. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4989-14.2015 · Cited by 149 · cited 1×
“…it is likely that oligomers are especially detrimental to cells, because they decrease cell viability more potently than tau fibrils (Flach et al. 2012), and antibodies against oligomers of tau are protective when administered to animal models of tauopathy (Castillo-Carranza et al. 2014, 2015).”
BackgroundFunk, K. E., Thomas, S. N., Schafer, K. N., Cooper, G. L., Liao, Z., Clark, D. J., Yang, A. J., & Kuret, J. (2014) · Biochemical Journal · doi:10.1042/bj20140372 · Cited by 142 · cited 2×
“Finally, methylation is the main modification of tau lysines observed in the normal brain (Funk et al. 2014), and levels of methylated tau are decreased in AD samples (Thomas et al. 2012).”
BackgroundA role for FKBP52 in tau protein function
Chambraud, B., Sardin, E., Giustiniani, J., Dounane, O., Schumacher, M., Goedert, M., & Baulieu, E.-E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914957107 · Cited by 140
Thomas, S. N., Funk, K. E., Wan, Y., Liao, Z., Davies, P., Kuret, J., & Yang, A. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0893-0 · Cited by 123 · cited 3×
“Multiple ubiquitination sites have been identified by mass spectroscopy analysis of PHF–tau preparations (Morishima-Kawashima et al. 1993; Cripps et al. 2006; Thomas et al. 2012); however, the requirement of these specific sites for the degradation of tau has not been confirmed.”
BackgroundDeveloping therapeutic approaches to tau, selected kinases, and related neuronal protein targets
Lee, V. M.-Y., Brunden, K. R., Hutton, M., & Trojanowski, J. Q. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006437 · Cited by 122 · cited 2×
“Another way is with therapeutic antibodies (Sigurdsson 2008; Chai et al. 2011) or molecules that block tau translation (Lee et al. 2011).”
BackgroundDistinct Therapeutic Mechanisms of Tau Antibodies
Funk, K. E., Mirbaha, H., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657924 · Cited by 111 · cited 1×
“In our view, antibodies that bind to tau, especially phospho-tau and oligomeric tau, seem to offer the most immediate pathway to clinically testing the tau-reduction hypothesis (Selenica et al. 2014; Funk et al. 2015; Ittner et al. 2015).”
BackgroundThe Role of Clusterin in Amyloid-β–Associated Neurodegeneration
Desikan, R. S., Thompson, W. K., Holland, D., Hess, C. P., Brewer, J. B., Zetterberg, H., Blennow, K., Andreassen, O. A., McEvoy, L. K., Hyman, B. T., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4560 · Cited by 79
FTDP-17 Tau Mutations Induce Distinct Effects on Aggregation and Microtubule Interactions
Combs, B., & Gamblin, T. C. (2012) · Biochemistry · doi:10.1021/bi3010818 · Cited by 79
A τ Fragment Containing a Repetitive Sequence Induces Bundling of Actin Filaments
Moraga, D. M., Nuñez, P., Garrido, J., & Maccioni, R. B. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03611.x · Cited by 56
Ramcharitar, J., Albrecht, S., Afonso, V. M., Kaushal, V., Bennett, D. A., & LeBlanc, A. C. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182a0a39f · Cited by 47
Selenica, M.-L. B., Davtyan, H., Housley, S. B., Blair, L. J., Gillies, A., Nordhues, B. A., Zhang, B., Liu, J., Gestwicki, J. E., Lee, D. C., et al. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0152-0 · Cited by 40 · cited 1×
“In our view, antibodies that bind to tau, especially phospho-tau and oligomeric tau, seem to offer the most immediate pathway to clinically testing the tau-reduction hypothesis (Selenica et al. 2014; Funk et al. 2015; Ittner et al. 2015).”
BackgroundSelf-citation
Cited by
Alquezar, C., Arya, S., & Kao, A. W. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.595532 · Cited by 367
Chen, J. J., Nathaniel, D. L., Raghavan, P., Nelson, M., Tian, R., Tse, E., Hong, J. Y., See, S. K., Mok, S.-A., Hein, M. Y., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009432 · Cited by 170
Self-citationDisease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Metadata
- Authors
- Young, Z. T., Mok, S. A., & Gestwicki, J. E.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-02-03
- Volume
- 8
- Issue
- 1
- Pages
- a024612
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2583700773
- Cited by
- 31
- References
- 52
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.